Flyrcado™ : A Breakthrough In Cardiac PET Imaging For...

Ajouter une nouvelle offre d'emploi Health

2025-09-27 08:28:34 - Traduire -

Flyrcado™ : A Breakthrough In Cardiac PET Imaging For Coronary Artery Disease

In a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD). Approved in September 2024 and commercially available in select U.S. markets...

0 Commentaires 0 Parts 634 Vue 0 Aperçu